Blossom covers the latest that goes on with the implementation of psychedelics. We keep track of the myriad companies working on making psychedelics a medicine that can help millions. Find our commentary on the business of psychedelics here, as well as our overview pages.

From drug policy reform to virtual reality, psychedelics are entering the 21st century | Guest post for Drugs&Me
How can we marry psychedelic capitalism & reciprocity? | Blossom speaks to Woven Science on their approach to indigenous communities, how they can give back, and provide a template for others to do so.
Expected to be north of $1 billion in revenue in the coming years | An investigation of the companies implementing psychedelic medicine
Blossom sits down with Zach Heigney, founder of The Trip Report | We discuss the impact of technology on psychedelics
In August 2021, Blossom interviewed dr. sc. hum. Henrik Jungaberle for the Psychedelics as Medicine Report - Third Edition. Henrik shared widely about the plans of the MIND Foundation, perspectives on therapist training, and the differences between the EU and the US.
In June 2021, PSYCH and Blossom conducted a nationally representative consumer survey in five countries. The aim of which was to gauge awareness of, and attitudes towards, the potential use of psychedelics for the treatment of a variety of mental health conditions. This section offers a preview of the topline analysis of the survey results.
Psychedelic news of July 2021 highlights benefits of psilocybin mushrooms, psychedelics for PTSD, and legalization.
March was a great month for research into psychedelics. The month featured a large-scale microdosing study where participants self-blinded their psychedelics. Other studies helped us form a framework around psychedelic retreats and how community factors help someone have better outcomes. Whilst other studies have, once again, shown the power of placebo and possible ways of dissecting that from other factors such as the active drug.
Apps made to help with a psychedelic experience | From preparation and information to apps to use during a psychedelic trip
February 2021 was another great month for psychedelic research and advocacy. Many brain (fMRI) studies were done and these help us better understand the mechanisms of action and why people respond in different ways to psychedelics. One study (in mice) even provided (more) evidence for neuronal growth.

Business Articles

Blossom‘s articles span the whole range of businesses that will implement, or are currently already implementing, psychedelics as medicine. From biomedical companies that invest in the next generation of molecules, to the therapists that will sit with patients, and all the way back to the producers of psychedelic molecules. Here we cover the full range of psychedelics as medicine. You can find all the companies in our Companies Database.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account